Details were scant, and Edward Conner, senior vice president and chief medical officer at Sangamo Therapeutics Inc., cautioned that "it's obviously still early days," but the Richmond, Calif.-based company clearly is encouraged by early data from the phase I/II ALTA trial evaluating SB-525, its cDNA gene therapy candidate to treat hemophilia A.